Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2015

View Archived Issues

Stabilization of alpha-crystallins improves lens opacity in cataract models

AbbVie reveals data on new BTK inhibitor

RP-10107, a potent glutaminase inhibitor

Novel anti-FOLR1 MAb KHK-2805 for ovarian cancer

Preclinical and clinical results of SM-04690 for the treatment of osteoarthritis

Collaborative research agreement to analyze novel anticancer agents by MSI

Immune responses seen with DNA-based vaccine INO-3112 in head and neck squamous cell carcinoma

Symic selects SB-061 as first osteoarthritis clinical candidate

Amylyx Pharmaceuticals receives funding to develop drug combination for ALS

Radius Health submits MAA for abaloparatide for postmenopausal osteoporosis

Phase III DUO study of duvelisib in CLL reaches target enrollment

Merck KGaA and Pfizer receive FDA breakthrough therapy designation for avelumab

Phylogica identifies new candidates that block intracellular MYC activity

Femtogenix discloses antineoplastic compounds

Kyungpook National University (KNU) and KNU Hospital patent PDK4 inhibitors

DTRM Biopharma patents BTK inhibitors

Medshine Discovery introduces ROCK inhibitors

Bayer Schering Pharma presents sGC activators

UM Pharmauji and Aurigene Discovery Technologies divulge DHODH inhibitors

Repurposed antihypertensive agent shows promise for Huntington's disease

Launch of pan-European MoTriColor consortium for colorectal cancer

First FDA approval of naloxone nasal spray for opioid overdose

Servier exercises licensing option with Cellectis for UCART-19

New company Vertice Pharma to acquire VistaPharm

Codiak BioSciences launched to develop exosome-based therapeutics and diagnostics

Aerpio reports full results from phase IIa trial of AKB-9778 in DME

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...